NCT07126873View on ClinicalTrials.gov

A Safety, Tolerability, and Efficacy Study of E-islet 01 in Participants With Type 1 Diabetes

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 11, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions
Diabetes Mellitus, Type 1Impaired Hypoglycemic AwarenessSevere Hypoglycemia
Interventions
BIOLOGICAL

Allogeneic Human E-islet (E-islet 01)

Allogeneic Human E-islet (E-islet 01), Infused into the hepatic portal vein

Trial Locations (1)

Unknown

RECRUITING

Shanghai Changzheng Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

EndoCell Therapeutics, Inc.

OTHER

NCT07126873 - A Safety, Tolerability, and Efficacy Study of E-islet 01 in Participants With Type 1 Diabetes | Biotech Hunter | Biotech Hunter